FRANKLIN LAKES, N.J.,
Dec. 28, 2017 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, issued the following statement
regarding today's clearance by the Ministry of Commerce of
the People's Republic of China
(MOFCOM) for BD to acquire C. R. Bard (NYSE: BCR), contingent on BD
divesting its soft tissue core needle biopsy product line:
"MOFCOM clearance was the final regulatory approval needed to
complete the Bard acquisition," said Vincent A. Forlenza, chairman and CEO of BD. "We
look forward to closing the transaction and welcoming Bard's
products and associates to the BD family."
The proposed acquisition remains subject to the satisfaction of
customary closing conditions. BD and Bard currently expect the
proposed acquisition to close on Friday,
Dec. 29.
Separately, BD's proposed divestiture of its soft tissue core
needle biopsy product line to Merit Medical is conditioned on
MOFCOM approval of Merit as the purchaser.
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has nearly 50,000 associates
across 50 countries who work in close collaboration with customers
and partners to help enhance outcomes, lower health care delivery
costs, increase efficiencies, improve health care safety and expand
access to health. For more information on BD, please visit
bd.com.
FORWARD-LOOKING STATEMENTS
This press release
contains "forward-looking statements" within the meaning of the
federal securities laws, including Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, related to the pending acquisition of Bard
by BD that involves substantial risks and uncertainties. These
statements are based on the current expectations of BD management,
and these statements speak only as of the date of this document. BD
undertakes no obligation to update any forward-looking statements
to reflect events or circumstances after the date hereof, except as
required by applicable laws or regulations.
Contacts:
|
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.617.2361
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
Monique_Dolecki@bd.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/bd-statement-on-mofcom-clearance-of-bard-acquisition-300575753.html
SOURCE BD (Becton, Dickinson and Company)